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Introduction
Infection caused by Streptococcus (S.) pneumoniae is a major cause of mortality and morbidity throughout the world. To prevent severe pneumococcal infections and their complications the Swedish National Board of Health and Welfare and the CDC Advisory Committee on Immunisation Practice recommend immunisation with 23-valent pneumococcal polysaccharide vaccine in persons >65 years of age and patients suffering from chronic illness at high risk for invasive pneumococcal disease (1, 2, 3) .
In patients with rheumatoid arthritis (RA) infections cause significant morbidity and mortality. Possible explanations include immune dysfunction associated with the disease itself, co-morbid illnesses and/or concomitant medication such as immunosuppressive drugs including long-term systemic glucocorticoids (4-10). The incidence of objectively confirmed infections in patients with RA was found to be increased compared to age-and sex matched subjects without RA. Also infections requiring hospitalisation including bacteremia/septicemia and pneumonia were reported to be significantly more frequent in RA patients (4) . The use of disease modifying anti-rheumatic drugs (DMARDs) including concomitant treatment with glucocorticoids has been found to be associated with increased risk for infections (7) .
Recently the introduction of anti-TNF treatments have contributed to a somewhat changed pattern of infections in RA (11) (12) (13) . More common infections, such as upper respiratory tract infections, have also been described among common adverse events and reasons for withdrawal of anti-TNF therapy in clinical trials as well as in observational studies (8, 14) . Doubled rates of serious infectious have also been reported (15) . Case reports of serious infections due to S. pneumoniae during anti-TNF therapy include pneumonia, severe pneumonia and necrotising fasciitis (infliximab) (16, 17) , and fatal septicaemia (etanercept) (18) .
Commercially available 23-valent pneumococcal capsular polysaccharide vaccine contains 23 purified capsular polysaccharide antigens of S. pneumoniae and the vaccine covers at least 85-90 % of the serotypes causing invasive pneumococcal infections (2) . The eight most common serotypes of invasive S. pneumoniae isolates reported to the Swedish Institute for Infectious Disease Control during 1988-1998 were serotypes: 14, 7F, 9V, 4,3,1, 23F, and 6B (19) .
Applying the CDC Advisory Committee on Immunisation Practice recommendations on patients with rheumatic disease, pneumococcal vaccination should be considered and encouraged in a majority of the patients in spite of convincing clinical evidence of efficacy (1, 2, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Also, in immunocompromised patients there is evidence of diminished or absent antibody responses to pneumococcal vaccine in certain groups (2, (30) (31) (32) (33) (34) (35) .
There is insufficient data from larger controlled trials on RA patients undergoing treatment with TNF-blocking agents and other DMARDs to allow more specific recommendations concerning pneumococcal vaccination. Despite the presumably decreased effectiveness of pneumococcal vaccine in some immunocompromised patients the potential benefits have so far been judged to justify its use. This study aims at assessing the effects of different therapy modalities including TNF blockers on the anti-capsular antibody response to vaccination in patients with longstanding RA and to compare the response obtained in healthy controls. 
Material and Methods

Quantitation of human IgG antibodies specific for S. pneumoniae capsular polysaccharides by ELISA
The results are presented as immunization response i.e. the ratio between post-and prevaccination concentrations. A positive immunization response was defined as a twofold or higher increase of the prevaccination antibody concentration. Since a protective level of serum antibody has not been strictly defined and may differ among serotypes these values were not used to identify individuals with probable/possible protective antibody levels.
Levels of serotype-specific pneumococcal IgG to 23F and 6B were measured using the WHO standard enzyme-linked immunosorbent assay for quantitation of human IgG antibodies specific for S. pneumoniae capsular polysaccharides (Pn PS ELISA) as previously described (39). Briefly, ELISA plates were coated with Pn PS. Dilutions of human sera absorbed with pneumococcal capsular polysaccharide were then added to the ELISA plates. The serotype specific antibodies (for 23F and 6B) were detected using goat anti-human IgG antibodies conjugated with alkaline phosphatase, followed by addition of the substrate, p-nitrophenyl phosphate. The optical density was measured at 405 nm using an ELISA plate reader. The optical density of the coloured end product is proportional to the amount of anti-capsular PS present in the serum. Calibration of the assay was made with an international reference serum that was kindly provided by dr C. Frasch, Bethesda, MD, USA (40). The lower limit of detection was 0.01 mg/L.
The distributions of the outcome variables were extremely skewed (Shapiro-Wilk W 0.24-0.74). Therefore we used non-parametric methods: the Mann-Whitney U-test for comparisons between groups, the Wilcoxon´s test for paired variables, and the Χ 2 test for ordinal variables.
P-values <0.05 were considered significant.
Results
Altogether groups, but compared with the time when anti-TNF was initiated there had been a significant reduction in the number of patients with high disease activity.
Antibody response
Prior to vaccination almost all participants had detectable levels of antibodies to both 23F and 6B (only two lacking antibodies to 23F, and seven to 6B). Prevaccination antibody concentrations were similar for the different treatment groups but tended to be higher among controls for both 23F and 6B ( Immunization responses i.e. the ratios between post-and prevaccination are summarized in table 2. There were large differences between the groups with regard to immune responses.
Responses were highest for TNF-blockers without MTX and lowest for MTX. Controls tended to respond better than MTX but this did not reach significance; p=0.059 for 23F and 0.058 for 6B. There were no significant differences between TNF-blockers+ MTX versus MTX with p=0.065 for 23F and p=0.246 for 6B.
The proportion of subjects having an immune response defined as ≥2-fold increase of the immune response ratio, differed between the treatment groups ( Figure 1-3 
Discussion
The major findings in this study are that anti-TNF therapy and prednisolone in low doses do not impair the antibody responses following pneumococcal vaccination, while methotrexate does reduce the response.
It is well known that immune responses to polysaccharides are lower than to protein antigens (20, 41) . Furthermore, precise protective levels have not been established (2, 41, 42) . A twofold increase of the antibody level was chosen as an indicator of immune responsiveness (1-3). Further uncertainties include variation of individual responses to different pneumococcal polysaccharide antigens (42) . This was also illustrated by our findings (table   2) . Our results show a somewhat lower combined responsiveness compared with a recent study in psoriatic arthritis patients (35), but this may merely reflect the choice of antigens analysed. The rationale for choosing 23F and 6B was that they represent two common serotypes known to be associated with invasive infections that are common among patients with underlying diseases in Sweden (19) .
The reduced immune response in the MTX group suggests that reduced responsiveness to exogenous or possibly endogenous antigens may be one of the modes of action of methotrexate which reduces rheumatoid inflammation. Recent reports of anti-rheumatic effects by B-cell depletion in RA patients suggest that decreased antibody production may decrease the rheumatic inflammation (43, 44 The analysis of age influence on immune response does not support the notion that high age reduces the likelihood of a positive immune response, at least not among RA patients. An interesting observation in this study is that patients above 60 years in TNF-blockers without MTX group showed similar immune responses as healthy controls below 30 years. However, the analyses of age influence in higher ages were not performed due the restricted number of patients. Because of the statistically different mean age of the control and treatment groups the age influences on the immune response can not be completely ruled out and may be considered as a limitation of this study. By contrast, therapy is important for the immune response in RA patients (table 3) .
The pre-vaccination presence of antibodies to 6B and 23F polysaccharide antigens presumably reflect antibodies acquired during life as a result of pneumococcal infections.
Prevaccination antibody levels were particularly high in some subjects in the healthy control group. Also, prevaccination levels of antibodies to pneumococcal polysaccharides are of limited value for selection of patients suitable for vaccination due to variations between different serotypes. The current findings suggest that pneumococcal vaccination should be performed prior to methotrexate initiation, whereas anti-TNF treatment and a low prednisolone dose do not preclude vaccination during ongoing therapy. Whether vaccinations actually reduce the true incidence of infectious complications in RA patients should be addressed in future trials. 
Figure legend
Figure1. Percentage (%) of patients with immune responses defined as a ≥2-fold increase in antibody levels to 23F. The groups were TNF-blockers without MTX = anti-TNF treatment ± DMARD excluding methotrexate, TNF-blockers +MTX = anti-TNF treatment + methotrexate ± other DMARD, MTX = methotrexate ± other DMARD excluding TNF blockers, and Control=healthy controls. Also levels of significance between groups are shown. 
